Faculty Profiles - akihide Tanimoto

Papers - akihide Tanimoto

Division display 121 - 140 of about 561 ／ All the affair displays >>

北薗育美, 霧島茉莉, 田崎貴嗣, 田畑和宏, 東美智代, 野口紘嗣, 簗詰伸太郎, 神宮司メグミ, 谷本昭英 . FDG-PET高集積を示した遺残副腎由来のOncocytomaの1例 . 診断病理39 ( 4 ) 319 - 325 2022.10Reviewed

Language：Japanese Publisher：(一社)日本病理学会

遺残副腎は異所性に認められる副腎皮質組織であり,腫瘍化は非常に稀である。80代女性の骨盤腔内にFDGの高集積を呈する腫瘍を認めた。腫瘍は右子宮広間膜内に卵巣とは離れて存在し,好酸性顆粒状の豊富な細胞質を有する腫瘍細胞のびまん性増殖からなり,腫瘍辺縁には非腫瘍性の副腎皮質組織を伴っていた。免疫染色でSF-1,mitochondria陽性であった。Lin-Weiss-Bisceglia criteriaを満たす所見はなく,遺残副腎由来のoncocytomaと診断した。(著者抄録)

researchmap

窪田恵美, 宿里亜李沙, 岩切かおり, 切田ゆかり, 霧島茉莉, 田崎貴嗣, 北薗育美, 田畑和宏, 東美智代, 谷本昭英 . 乳腺転移を来した膵solid-pseudopapillary neoplasmの1例 . 日本臨床細胞学会九州連合会雑誌53 79 - 82 2022.7Reviewed

Language：Japanese Publisher：日本臨床細胞学会-九州連合会

背景膵solid-pseudopapillary neoplasm(以下、SPN)は、膵外分泌腫瘍の1～3%を占める稀な腫瘍である。今回、乳腺細胞診において原発性乳癌との鑑別に苦慮した膵SPNの乳腺転移の1例を経験したので報告する。症例 50代女性。7年前に手術された膵SPN術後の定期検診にて左乳腺外側に1cm大の結節を指摘された。原発性乳癌が疑われ、針生検及び穿刺針洗浄細胞診が施行された。穿刺針洗浄細胞診で、血性背景に乳頭状、管状あるいは孤立散在性の異型細胞を多数認め、血管性間質を軸とした重積性を示す集塊も存在していた。核偏在傾向や核溝も見られ、浸潤性乳管癌充実型や粘液癌Type Bを疑った。摘出生検では、シート状構造を示す腫瘍細胞と淡好塩基性を示す疎な線維性間質を認め、偽乳頭状構造も認めた。免疫染色では、β-cateninが腫瘍細胞の核・細胞質に陽性であった。以上の所見から膵SPNの乳腺転移と判断した。結論原発性乳癌との鑑別に苦慮した膵SPNの乳腺転移の一例を経験した。膵SPNの肝や腹腔以外への転移は稀ではあるが、臨床情報に留意し検鏡することで診断し得ると考えられた。(著者抄録)

researchmap

Nayuta Higa, Toshiaki Akahane, Taiji Hamada, Hajime Yonezawa, Hiroyuki Uchida, Ryutaro Makino, Shoji Watanabe, Tomoko Takajo, Seiya Yokoyama, Mari Kirishima, Kei Matsuo, Shingo Fujio, Ryosuke Hanaya, Akihide Tanimoto, Koji Yoshimoto . Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma. . Cancer medicine12 ( 1 ) 49 - 60 2022.6Reviewed International journal

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: We aimed to evaluate the mutation profile, transcriptional variants, and prognostic impact of the epidermal growth factor receptor (EGFR) gene in isocitrate dehydrogenase (IDH)-wildtype glioblastomas (GBMs). METHODS: We sequenced EGFR, evaluated the EGFR splicing profile using a next-generation sequencing oncopanel, and analyzed the outcomes in 138 grade IV IDH-wildtype GBM cases. RESULTS: EGFR mutations were observed in 10% of GBMs. A total of 23.9% of the GBMs showed EGFR amplification. Moreover, 25% of the EGFR mutations occurred in the kinase domain. Notably, EGFR alterations were a predictor of good prognosis (p = 0.035). GBM with EGFR alterations was associated with higher Karnofsky Performance Scale scores (p = 0.014) and lower Ki-67 scores (p = 0.005) than GBM without EGFR alterations. EGFRvIII positivity was detected in 21% of EGFR-amplified GBMs. We identified two other EGFR variants in GBM cases with deletions of exons 6-7 (Δe 6-7) and exons 2-14 (Δe 2-14). In one case, the initial EGFRvIII mutation transformed into an EGFR Δe 2-14 mutation during recurrence. CONCLUSIONS: We found that the EGFR gene profiles of GBM differ among cohorts and that EGFR alterations are good prognostic markers of overall survival in patients with IDH-wildtype GBM. Additionally, we identified rare EGFR variants with longitudinal and temporal transformations of EGFRvIII.

DOI： 10.1002/cam4.4939

PubMed

researchmap

Mari Kirishima, Seiya Yokoyama, Kei Matsuo, Taiji Hamada, Michiko Shimokawa, Toshiaki Akahane, Tomoyuki Sugimoto, Hirohito Tsurumaru, Matsujiro Ishibashi, Yuko Mataki, Takao Ootsuka, Mitsuharu Nomoto, Chihiro Hayashi, Akihiko Horiguchi, Michiyo Higashi, Akihide Tanimoto . Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis. . BMC microbiology22 ( 1 ) 147 - 147 2022.5Reviewed International journal

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: The microbial population of the intestinal tract and its relationship to specific diseases has been extensively studied during the past decade. However, reports characterizing the bile microbiota are rare. This study aims to investigate the microbiota composition in patients with pancreaticobiliary cancers and benign diseases by 16S rRNA gene amplicon sequencing and to evaluate its potential value as a biomarker for the cancer of the bile duct, pancreas, and gallbladder. RESULTS: We enrolled patients who were diagnosed with cancer, cystic lesions, and inflammation of the pancreaticobiliary tract. The study cohort comprised 244 patients. We extracted microbiome-derived DNA from the bile juice in surgically resected gallbladders. The microbiome composition was not significantly different according to lesion position and cancer type in terms of alpha and beta diversity. We found a significant difference in the relative abundance of Campylobacter, Citrobacter, Leptotrichia, Enterobacter, Hungatella, Mycolicibacterium, Phyllobacterium and Sphingomonas between patients without and with lymph node metastasis. CONCLUSIONS: There was a significant association between the relative abundance of certain microbes and overall survival prognosis. These microbes showed association with good prognosis in cholangiocarcinoma, but with poor prognosis in pancreatic adenocarcinoma, and vice versa. Our findings suggest that pancreaticobiliary tract cancer patients have an altered microbiome composition, which might be a biomarker for distinguishing malignancy.

DOI： 10.1186/s12866-022-02557-3

PubMed

researchmap

野元翔平, 上笹貫太郎, 田畑和宏, 谷本昭英, 坂本泰二 . 臨床報告上眼瞼Merkel細胞癌の1例 . 臨床眼科76 ( 5 ) 597 - 602 2022.5Reviewed

窪田恵美, 岩切かおり, 古家淳行, 亀澤雅, 霧島茉莉, 田崎貴嗣, 北薗育美, 東美智代, 谷本昭英 . 診断に苦慮した耳下腺の乳腺相似分泌癌の一例 . 日本臨床細胞学会雑誌61 ( Suppl.1 ) 281 - 281 2022.5Reviewed

Michiyo Higashi, Taiji Hamada, Ken Sasaki, Yusuke Tsuruda, Masataka Shimonosono, Ikumi Kitazono, Mari Kirishima, Takashi Tasaki, Hirotsugu Noguchi, Kazuhiro Tabata, Masanori Hisaoka, Yoshihiko Fukukura, Takao Ohtsuka, Akihide Tanimoto . Esophageal plexiform fibromyxoma: A case report with molecular analysis for MALAT1-GLI1 fusion. . Pathology, research and practice233 153878 - 153878 2022.5Reviewed International journal

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

Plexiform fibromyxoma (PFM) is a rare gastrointestinal tract tumor that develops in the stomach in most cases. Here, we report an extremely rare case of esophageal PFM. A female in her mid-30 s presented with difficulty in swallowing and breathing. Endoscopic examination revealed a submucosal tumor measuring approximately 45 × 50 mm in the upper thoracic esophagus. The biopsied specimen did not show definite histological evidence of gastrointestinal stromal tumors (GISTs). Since imatinib administration based on a clinical diagnosis of GIST did not show a therapeutic effect for tumor reduction, tumor resection was performed. The resected tumor exhibited proliferation of spindle tumor cells with abundant myxoid and vascular stroma separated by a muscular layer, indicating a plexiform arrangement. Immunohistochemical analysis demonstrated that the tumor cells diffusely expressed vimentin and alpha-smooth muscle actin, but not desmin, c-kit, DOG1, and CD34. MALAT1-GLI1 fusion was detected in formalin-fixed paraffin-embedded tissue using RT-PCR and Sanger sequencing. The results suggested that a fibromyxoid tumor can develop in the esophagus, showing an identical histology and MALAT1-GLI1 fusion to gastric PFM.

DOI： 10.1016/j.prp.2022.153878

PubMed

researchmap

赤羽俊章, 比嘉那優大, 霧島茉莉, 内田裕之, 米澤大, 吉本幸司, 谷本昭英 . 頭頸部・脳腫瘍用カスタム融合遺伝子パネルで認められた、IDH1変異陽性神経膠腫のNTRK融合遺伝子 . Brain Tumor Pathology39 ( Suppl. ) 086 - 086 2022.5Reviewed

比嘉那優大, 赤羽俊章, 横山勢也, 米澤大, 内田裕之, 浜田大治, 霧島茉莉, 谷本昭英, 花谷亮典, 吉本幸司 . IDH wild-type GBMにおけるPDGFRA amplificationおよびMGMTpの予後への影響 . Brain Tumor Pathology39 ( Suppl. ) 086 - 086 2022.5Reviewed

Kosuke Fukuda, Takaaki Arigami, Koki Tokuda, Shigehiro Yanagita, Daisuke Matsushita, Yota Kawasaki, Satoshi Iino, Ken Sasaki, Akihiro Nakajo, Mari Kirishima, Akihide Tanimoto, Hitoshi Tsubouchi, Hiroshi Kurahara, Takao Ohtsuka . Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report. . Surgical case reports8 ( 1 ) 58 - 58 2022.4Reviewed International journal

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: In recent years, conversion surgery after chemotherapy has been considered a promising strategy for improving the prognosis of patients with stage IV gastric cancer. However, there are few reports on conversion gastrectomy after second-line chemotherapy. Here, we report a case of long-term survival of a patient with liver metastases from gastric cancer who underwent conversion surgery after second-line chemotherapy with ramucirumab and paclitaxel. CASE PRESENTATION: A 77-year-old man complaining of weight loss was diagnosed with human epidermal growth factor receptor 2-positive gastric cancer with multiple liver metastases. Although the patient initially received trastuzumab-based chemotherapy, it was discontinued, because he experienced trastuzumab-induced infusion reactions. Thereafter, he was treated with six courses of S-1 plus cisplatin and six courses of ramucirumab plus paclitaxel as the first- and second-line regimens, respectively. The primary tumor and liver metastases remarkably shrank, and the reduction rate of the measurable metastatic liver lesions was 81.1%. According to the Response Evaluation Criteria in Solid Tumors, the patient responded partially. Therefore, he underwent total gastrectomy with D2 lymphadenectomy and partial hepatectomy of segments 3 and 4. Pathological examination revealed tumor invasion into the muscularis propria, a grade 1a histological response, and no lymph node metastases. No viable cancer cells were identified in the specimens resected from liver segments 3 and 4. Accordingly, the patient was pathologically diagnosed with stage IB (ypT2N0M0). Postoperatively, the patient received adjuvant chemotherapy with S-1 for 6 months, and he survived without recurrence for 42 months after conversion surgery. CONCLUSIONS: Conversion surgery might be clinically useful for improving survival in certain patients with gastric cancer, including those who previously received second-line chemotherapy.

DOI： 10.1186/s40792-022-01412-x

PubMed

researchmap

大庭優士, 安田俊介, 鶴薗健太郎, 冨岡勇也, 松山崇弘, 三山英夫, 末次隆行, 水野圭子, 井上博雅, 田畑和宏, 谷本昭英 . イピリムマブ+ニボルマブ+カルボプラチン+ペメトレキセド併用療法で視力の改善が得られた脈絡膜転移を有する肺腺癌の1例 . 肺癌62 ( 2 ) 141 - 141 2022.4Reviewed

Ikumi Kitazono, Toshiaki Akahane, Yusuke Kobayashi, Shintaro Yanazume, Kazuhiro Tabata, Takashi Tasaki, Hirotsugu Noguchi, Mari Kirishima, Michiyo Higashi, Hiroaki Kobayashi, Akihide Tanimoto . Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common POLE Mutation to Endometrial Endometroid Carcinoma: A Case Report. . International journal of surgical pathology30 ( 8 ) 10668969221088880 - 10668969221088880 2022.3Reviewed International journal

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

POLE mutation-type endometrial cancer is characterized by an extremely high tumor mutation burden. Most POLE mutation-type endometrial cancers are histologically endometrioid carcinomas, and POLE mutation-type carcinosarcomas are rare among endometrial cancers. We report a case of endometrial and pelvic cancer in a 53-year-old woman who was analyzed using next-generating sequencing. The endometrial lesion harbored a p.T457del POLE mutation with an elevated tumor mutation burden and low microsatellite instability. The pelvic lesion showed divergent histological features, consisting of high-grade endometrioid carcinoma, neuroendocrine carcinoma, and chondrosarcoma. In addition to the common POLE mutation detected in the endometrial lesion, the pelvic lesion in each element showed additional gene mutations in a hierarchical manner. Therefore, it is indicated that the p.T457del POLE mutation is a pathogenic mutation and may be related to POLE mutation-induced carcinogenesis and divergent morphogenesis in endometrial cancer.

DOI： 10.1177/10668969221088880

PubMed

researchmap

Aya Takeda, Kazuhiro Ueda, Masaya Aoki, Toshiyuki Nagata, Go Kamimura, Tadashi Umehara, Takuya Tokunaga, Kazuhiro Tabata, Akihide Tanimoto, Masami Sato . Altered lymphatic structure and function in pleural anthracosis: negative role in skip N2 metastasis. . European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery62 ( 3 ) 2022.2Reviewed International journal

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVES: The present study investigated whether or not pleural anthracosis is associated with changes in the pleural lymphatic structures or function, which would interfere with nodal skip metastasis. METHODS: This study comprised 2 different case series. In the first series, we observed pleural lymphatic drainage using near-infrared fluorescent endoscopy by the subpleural injection of indocyanine green immediately after thoracotomy for lung cancer. We also performed a histological assessment of the pleura. In the second series, we reviewed the nodal metastatic pattern (skip or non-skip metastasis) in pathological N2 lung cancer involving the pleura. These findings were compared with the severity of pleural anthracosis, which was quantified by thoracoscopic vision and a software-based imaging analysis. RESULTS: In the first series (n = 42), pleural lymphatic drainage was not visualized in 19 (45%) patients who had relatively severe anthracosis, while it was visualized in the remaining 23 (55%) patients who had relatively minimal anthracosis. Histologically, severe anthracosis was associated with pleural thickening accompanied by a decreased incidence of straight-running lymphatic vessels and, in turn, an increased incidence of short lymphatic vessels, which was suggested to be the result of pleural remodelling. In the second series (n = 53), a skip metastatic pattern was found in 24 (45%) patients who predominantly had less-severe anthracosis, while a non-skip metastatic pattern was found in 29 (55%) patients who predominantly had severe anthracosis. CONCLUSIONS: Pleural anthracosis was associated with pathological changes in the pleural lymphatics and decreased pleural lymphatic drainage, thereby interfering with nodal skip metastasis.

DOI： 10.1093/ejcts/ezac123

PubMed

researchmap

Ikumi Kitazono, Yusuke Kobayashi, Toshiaki Akahane, Tomomi Yamaguchi, Shintaro Yanazume, Sachio Nohara, Ippei Sakamoto, Kazuhiro Tabata, Takashi Tasaki, Hiroaki Kobayashi, Akihide Tanimoto . ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma. . Pathology, research and practice230 153743 - 153743 2022.2Reviewed International journal

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

Ancillary immunohistochemical tools can facilitate an integrated diagnosis of endometrial pathology. According to The Cancer Genome Atlas classification, endometrial cancers are of four molecular subtypes: mismatch repair (MMR)-deficient (MMR-d), p53 mutation (p53mut), DNA polymerase epsilon (POLE) mutation (POLEmut), and no specific molecular profile (NSMP). As the specific histological and immunohistochemical features of POLEmut and NSMP subtypes are unknown, these cancers are categorized based on molecular analysis. In this study, we analyzed POLEmut-subtype endometrioid carcinoma (EC) using a custom-made cancer gene panel and the Catalog of Somatic Mutations in Cancer (COSMIC) database, extracted a characteristic genome profile, and identified an immunohistochemical marker that could be used as a diagnostic tool. The results indicated that the POLEmut-subtype EC exhibited nonsense mutations in the ataxia telangiectasia mutated (ATM) gene and a subsequent loss of ATM expression, which was monitored through immunohistochemical analysis. Moreover, analyses using the COSMIC database indicated that POLEmut-subtype EC cases often harbored similar ATM nonsense mutations. These results suggest that ATM expression is a potential immunohistochemical marker for the differential diagnosis of POLEmut- and NSMP-subtype EC. DATA AVAILABILITY: The data supporting the findings of this study are available upon request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions.

DOI： 10.1016/j.prp.2021.153743

PubMed

researchmap

Taiji Hamada, Toshiaki Akahane, Seiya Yokoyama, Nayuta Higa, Mari Kirishima, Kei Matsuo, Michiko Shimokawa, Koji Yoshimoto, Akihide Tanimoto . An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors. . Scientific reports12 ( 1 ) 1275 - 1275 2022.1Reviewed International journal

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

Understanding human genome alterations is necessary to optimize genome-based cancer therapeutics. However, some newly discovered mutations remain as variants of unknown significance (VUS). Here, the mutation c.1403A > G in exon 10 of the platelet-derived growth factor receptor-alpha (PDGFRA) gene, a VUS found in adult glioblastoma multiforme (GBM), was introduced in human embryonal kidney 293 T (HEK293T) cells using genome editing to investigate its potential oncogenic functions. Genome editing was performed using CRISPR/Cas9; the proliferation, drug sensitivity, and carcinogenic potential of genome-edited cells were investigated. We also investigated the mechanism underlying the observed phenotypes. Three GBM patients carrying the c.1403A > G mutation were studied to validate the in vitro results. The c.1403A > G mutation led to a splice variant (p.K455_N468delinsN) because of the generation of a 3'-acceptor splice site in exon 10. PDGFRA-mutated HEK293T cells exhibited a higher proliferative activity via PDGFRα and the cyclin-dependent kinase (CDK)4/CDK6-cyclin D1 signaling pathway in a ligand-independent manner. They showed higher sensitivity to multi-kinase, receptor tyrosine kinase, and CDK4/CDK6 inhibitors. Of the three GBM patients studied, two harbored the p.K455_N468delinsN splice variant. The splicing mutation c.1403A > G in PDGFRA is oncogenic in nature. Kinase inhibitors targeting PDGFRα and CDK4/CDK6 signaling should be evaluated for treating GBM patients harboring this mutation.

DOI： 10.1038/s41598-022-05391-9

PubMed

researchmap

Mari Kirishima, Toshiaki Akahane, Nayuta Higa, Hajime Yonezawa, Hiroyuki Uchida, Ikumi Kitazono, Michiyo Higashi, Koji Yoshimoto, Akihide Tanimoto . Integrated diagnosis of adult-type glioma according to 2021 World Health Organization classification: Analysis of 184 cases using a custom-made next-generation sequencing panel. . Pathology international72 ( 3 ) 207 - 210 2022.1Reviewed International journal

Nayuta Higa, Toshiaki Akahane, Seiya Yokoyama, Hajime Yonezawa, Hiroyuki Uchida, Tomoko Takajo, Ryosuke Otsuji, Taiji Hamada, Kei Matsuo, Mari Kirishima, Nobuhiro Hata, Ryosuke Hanaya, Akihide Tanimoto, Koji Yoshimoto . Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma . Neuro-Oncology Advances4 ( 1 ) vdac097 2022.1Reviewed International journal

Language：English Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

Background

Platelet-derived growth factor receptor alpha (PDGFRA) is the second most frequently mutated tyrosine kinase receptor in glioblastoma (GBM). However, the prognostic impact of PDGFRA amplification on GBM patients remains unclear. Herein, we evaluated this impact by retrospectively analyzing outcomes of patients with IDH wild-type GBM.

Methods

Using a custom-made oncopanel, we evaluated PDGFRA gain/amplification in 107 GBM samples harboring wild-type IDH, along with MGMT promoter (MGMTp) methylation status.

Results

We detected PDGFRA gain/amplification in 31 samples (29.0%). PDGFRA gain/amplification predicted poor prognosis (P = .003). Compared to unamplified PDGFRA, PDGFRA gain/amplification in GBM was associated with higher patient age (P = .031), higher Ki-67 score (P = .019), and lower extent of surgical resection (P = .033). Unmethylated MGMTp also predicted poor prognosis (P = .005). As PDGFRA gain/amplification and unmethylated MGMTp were independent factors for poor prognosis in multivariate analyses, we grouped GBM cases based on PDGFRA and MGMTp status: poor (PDGFRA gain/amplification and unmethylated MGMTp), intermediate (PDGFRA gain/amplification or unmethylated MGMTp), and good (PDGFRA intact and methylated MGMTp) prognosis. The Kaplan-Meier survival analysis indicated that these groups significantly correlated with the OS of GBM patients (P &lt; .001).

Conclusions

Here we report that PDGFRA gain/amplification is a predictor of poor prognosis in IDH wild-type GBM. Combining PDGFRA gain/amplification with MGMTp methylation status improves individual prognosis prediction in patients with IDH wild-type GBM.

DOI： 10.1093/noajnl/vdac097

PubMed

researchmap

Other Link： https://academic.oup.com/noa/article-pdf/4/1/vdac097/45178840/vdac097.pdf

Hiroki Iwaizako, Takuro Nishikawa, Ikumi Kitazono, Akihide Tanimoto, Yasuhiro Okamoto . Unknown primary malignant small round cell tumor masquerading as acute leukemia. . Pediatrics international : official journal of the Japan Pediatric Society64 ( 1 ) e15158 2022.1Reviewed International journal

Takuya Yoshimura, Shotaro Higashi, Sohsuke Yamada, Hirotsugu Noguchi, Mitsuharu Nomoto, Hajime Suzuki, Takayuki Ishida, Hirotaka Takayama, Yuka Hirano, Masaru Yamashita, Akihide Tanimoto, Norifumi Nakamura . PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland. . Cancers14 ( 1 ) 2021.12Reviewed International journal

Language：English Publishing type：Research paper (scientific journal)

Mucoepidermoid carcinoma (MEC) is one of the most common malignant salivary gland carcinomas, but no effective treatment strategy has been established other than surgical resection. Purkinje cell protein (PCP) 4/peptide (PEP) 19 is a calmodulin-binding antiapoptotic peptide that is expressed and inhibits apoptosis in human breast cancer cells. Human epidermal growth factor receptor 2 (HER2) is an epidermal growth factor that has been implicated in the pathogenesis of many carcinomas, particularly breast and gastric carcinomas. In the present study, we performed immunohistochemical analyses of samples from 73 patients who underwent surgical resection for MEC of the salivary gland using antibodies against PCP4/PEP19 and HER2. PCP4/PEP19 expression was related to better prognosis, while HER2 expression was associated with worse prognosis. Patients that were PCP4/PEP19-positive and HER2-negative showed similar outcomes to PCP4/PEP19 and HER2 alone. Therefore, PCP4/PEP19 and HER2 are predicted to play important roles in the pathogenesis and progression of MEC.

DOI： 10.3390/cancers14010054

PubMed

researchmap

田代葵子, 上笹貫太郎, 堀之内道子, 谷本昭英, 坂本泰二 . 臨床報告インターフェロン-β結膜下注射が奏効した結膜悪性黒色腫の1例 . 臨床眼科75 ( 13 ) 1650 - 1656 2021.12Reviewed

　 PREV - NEXT 　

<akihide Tanimoto>

Papers - akihide Tanimoto